Induction of a unique isoform of the NCOA7 oxidation resistance gene by interferon β-1b

Journal of Interferon and Cytokine Research

Volumn 35, Issue 3, 2015, Pages 186-199

  Yu, Lijian ^a   Croze, Ed ^b,c   Yamaguchi, Ken D ^b,d   Tran, Tiffany ^b,e   Reder, Anthony T ^f   Litvak, Vladimir ^a   Volkert, Michael R ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b Global Biologics Research   (United States)

^c IRIS Bay   (United States)

^d Knowledge Synthesis Inc   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON BETA SERINE; JANUS KINASE; LIPOPOLYSACCHARIDE; NUCLEAR RECEPTOR COACTIVATOR 7; PROTEIN; STAT PROTEIN; UNCLASSIFIED DRUG; BETA INTERFERON; INTERFERON RECEPTOR; ISOPROTEIN; NCOA7 PROTEIN, HUMAN; NUCLEAR RECEPTOR COACTIVATOR;

ANTIOXIDANT ACTIVITY; ARTICLE; BRAIN CELL; CONTROLLED STUDY; DNA RESPONSIVE ELEMENT; EXON; FETUS; FIBROSARCOMA CELL; GENE; GENE EXPRESSION; HUMAN; HUMAN CELL; INFLAMMATION; MASTOCYTOMA CELL LINE; MULTIPLE SCLEROSIS; NCOA7 GENE; NEUROBLASTOMA CELL; OXIDATIVE STRESS; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN FUNCTION; PROTEIN STRUCTURE; REGULATORY MECHANISM; REGULATORY SEQUENCE; SIGNAL TRANSDUCTION; AMINO ACID SEQUENCE; CELL LINE; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; MOLECULAR GENETICS; MONONUCLEAR CELL; OXIDATION REDUCTION REACTION; PHYSIOLOGY; PROCEDURES; PROTEIN TERTIARY STRUCTURE;

BACTERIA (MICROORGANISMS);

AMINO ACID SEQUENCE; CELL LINE; HUMANS; IMMUNOTHERAPY; INTERFERON-BETA; JANUS KINASES; LEUKOCYTES, MONONUCLEAR; MOLECULAR SEQUENCE DATA; MULTIPLE SCLEROSIS; NUCLEAR RECEPTOR COACTIVATORS; OXIDATION-REDUCTION; OXIDATIVE STRESS; PROTEIN ISOFORMS; PROTEIN STRUCTURE, TERTIARY; RECEPTORS, INTERFERON; REGULATORY ELEMENTS, TRANSCRIPTIONAL; SIGNAL TRANSDUCTION; STAT TRANSCRIPTION FACTORS;

EID: 84929171188     PISSN: 10799907     EISSN: 15577465     Source Type: Journal    
DOI: 10.1089/jir.2014.0115     Document Type: Article

References (66)

1. Akaike T, Suga M, Maeda H. 1998. Free radicals in viral pathogenesis: molecular mechanisms involving superoxide and NO. Proc Soc Exp Biol Med 217(1):64-73.
2. Amor S, Puentes F, Baker D, van der Valk P. 2010. Inflammation in neurodegenerative diseases. Immunology 129(2):154-169.
3. Arnason BG, Dayal A, Qu ZX, Jensen MA, Genc K, Reder AT. 1996. Mechanisms of action of interferon-beta in multiple sclerosis. Springer Semin Immunopathol 18(1):125-148.
4. Butterfield DA. 2006. Oxidative stress in neurodegenerative disorders. Antioxid Redox Signal 8(11-12):1971-1973.
5. Butterfield DA, Perluigi M, Reed T, Muharib T, Hughes CP, Robinson RA, Sultana R. 2012. Redox proteomics in selected neurodegenerative disorders: from its infancy to future applications. Antioxid Redox Signal 17(11):1610-1655.
6. Carninci P, Sandelin A, Lenhard B, Katayama S, Shimokawa K, Ponjavic J, Semple CA, Taylor MS, Engstrom PG, Frith MC, Forrest AR, Alkema WB, Tan SL, Plessy C, Kodzius R, Ravasi T, Kasukawa T, Fukuda S, Kanamori-Katayama M, Kitazume Y, Kawaji H, Kai C, Nakamura M, Konno H, Nakano K, Mottagui-Tabar S, Arner P, Chesi A, Gustincich S, Persichetti F, Suzuki H, Grimmond SM, Wells CA, Orlando V, Wahlestedt C, Liu ET, Harbers M, Kawai J, Bajic VB, Hume DA, Hayashizaki Y. 2006. Genome-wide analysis of mammalian promoter architecture and evolution. Nat Genet 38(6):626-635.
7. Columbano A, Rajalakshmi S, Sarma DS. 1981. Requirement of cell proliferation for the initiation of liver carcinogenesis as assayed by three different procedures. Cancer Res 41(6):2079-2083.
8. Croze E. 2010. Differential gene expression and translational approaches to identify biomarkers of interferon beta activity in multiple sclerosis. J Interferon Cytokine Res 30(10):743-749.
9. Croze E, Veichko S, Tran T, Yamaguchi KD, Salamon H, Reder AT, Kanppertz V, Paz P. 2009. Betaseron induces a novel alternate start transcript in cells obtained from relapsing-remitting multiple sclerosis patients and human brain that is associated with control of oxidative resistance. Multiple sclerosis 15(S138):475.
10. Croze E, Yamaguchi KD, Knappertz V, Reder AT, Salamon H. 2012. Interferon-beta-1b-induced short-and long-term signatures of treatment activity in multiple sclerosis. Pharmacogenomics J 15 (S138):475.
11. Croze E, Yamaguchi KD, Knappertz V, Reder AT, Salamon H. 2013. Interferon-beta-1b-induced short-and long-term signatures of treatment activity in multiple sclerosis. Pharmacogenomics J 13(5):443-451.
12. Dauer W, Przedborski S. 2003. Parkinson's disease: mechanisms and models. Neuron 39(6):889-909.
13. Der SD, Zhou A, Williams BR, Silverman RH. 1998. Identification of genes differentially regulated by interferon alpha, beta, or gamma using oligonucleotide arrays. Proc Natl Acad Sci U S A 95(26):15623-15628.
14. Durand M, Kolpak A, Farrell T, Elliott NA, Shao W, Brown M, Volkert MR. 2007. The OXR domain defines a conserved family of eukaryotic oxidation resistance proteins. BMC Cell Biol 8:13.
15. Elliott NA, Volkert MR. 2004. Stress induction and mito-chondrial localization of Oxr1 proteins in yeast and humans. Mol Cell Biol 24(8):3180-3187.
16. Fussell KC, Udasin RG, Smith PJ, Gallo MA, Laskin JD. 2011. Catechol metabolites of endogenous estrogens induce redox cycling and generate reactive oxygen species in breast epithelial cells. Carcinogenesis 32(8):1285-1293.
17. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S, Ellis B, Gautier L, Ge Y, Gentry J, Hornik K, Hothorn T, Huber W, Iacus S, Irizarry R, Leisch F, Li C, Maechler M, Rossini AJ, Sawitzki G, Smith C, Smyth G, Tierney L, Yang JY, Zhang J. 2004. Bioconductor: open software development for computational biology and bioin-formatics. Genome Biol 5(10):R80.
18. Gonsette RE. 2008. Neurodegeneration in multiple sclerosis: the role of oxidative stress and excitotoxicity. J Neurol Sci 274(1-2):48-53.
19. Guillemard E, Varano B, Belardelli F, Quero AM, Gessani S. 1999. Inhibitory activity of constitutive nitric oxide on the expression of alpha/beta interferon genes in murine peritoneal macrophages. J Virol 73(9):7328-7333.
20. Hagen TM, Huang S, Curnutte J, Fowler P, Martinez V, Wehr CM, Ames BN, Chisari FV. 1994. Extensive oxidative DNA damage in hepatocytes of transgenic mice with chronic active hepatitis destined to develop hepatocellular carcinoma. Proc Natl Acad Sci U S A 91(26):12808-12812.
21. He F, Li X, Spatrick P, Casillo R, Dong S, Jacobson A. 2003. Genome-wide analysis of mRNAs regulated by the nonsensemediated and 5¢ to 3¢ mRNA decay pathways in yeast. Mol Cell 12(6):1439-1452.
22. Jin Y, Penning TM. 2007. Aldo-keto reductases and bioactiva-tion/detoxication. Annu Rev Pharmacol Toxicol 47:263-292.
23. Kaur C, Ling EA. 2008. Antioxidants and neuroprotection in the adult and developing central nervous system. Curr Med Chem 15(29):3068-3080.
24. Kerr IM, Stark GR. 1991. The control of interferon-inducible gene expression. FEBS Lett 285(2):194-198.
25. Kimura K, Wakamatsu A, Suzuki Y, Ota T, Nishikawa T, Yamashita R, Yamamoto J, Sekine M, Tsuritani K, Wakaguri H, Ishii S, Sugiyama T, Saito K, Isono Y, Irie R, Kushida N, Yoneyama T, Otsuka R, Kanda K, Yokoi T, Kondo H, Wagatsuma M, Murakawa K, Ishida S, Ishibashi T, Takahashi-Fujii A, Tanase T, Nagai K, Kikuchi H, Nakai K, Isogai T, Sugano S. 2006. Diversification of transcriptional modulation: large-scale identification and characterization of putative alternative promoters of human genes. Genome Res 16(1):55-65.
26. Kurtzke JF. 1983. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33(11):1444-1452.
27. Li D, Ferrari M, Ellis EM. 2012. Human aldo-keto reductase AKR7A2 protects against the cytotoxicity and mutagenicity of reactive aldehydes and lowers intracellular reactive oxygen species in hamster V79-4 cells. Chem Biol Interact 195(1):25-34.
28. Liehr JG, Ulubelen AA, Strobel HW. 1986. Cytochrome P-450-mediated redox cycling of estrogens. J Biol Chem 261(36):16865-16870.
29. Litvak V, Ratushny AV, Lampano AE, Schmitz F, Huang AC, Raman A, Rust AG, Bergthaler A, Aitchison JD, Aderem A. 2012. A FOXO3-IRF7 gene regulatory circuit limits inflammatory sequelaeof antiviral responses. Nature 490(7420):421-425.
30. Lutfalla G, Holland SJ, Cinato E, Monneron D. Reboul J, Rogers NC, Smith JM, Stark GR, Gardiner K, Mogensen KE, et al. 1995. Mutant U5A cells are complemented by an interferon-alpha beta receptor subunit generated by alternative processing of a new member of a cytokine receptor gene cluster. EMBO J 14(20):5100-5108.
31. McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, McFarland HF, Paty DW, Polman CH, Reingold SC, Sandberg-Wollheim M, Sibley W, Thompson A, van den Noort S, Weinshenker BY, Wolinsky JS. 2001. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 50(1):121-127.
32. Melo A, Monteiro L, Lima RM, Oliveira DM, Cerqueira MD, El-Bacha RS. 2011. Oxidative stress in neurodegenerative diseases: mechanisms and therapeutic perspectives. Oxid Med Cell Longev 2011:467180.
33. Michaels ML, Cruz C, Grollman AP, Miller JH. 1992a. Evidence that MutY and MutM combine to prevent mutations by an oxidatively damaged form of guanine in DNA. Proc Natl Acad Sci USA 89:7022-7025.
34. Michaels ML, Miller JH. 1992. The GO system protects organisms from the mutagenic effect of the spontaneous lesion 8-hydroxyguanine (7, 8-dihydro-8-oxoguanine). J Bacteriol 174(20):6321-6325.
35. Michaels ML, Tchou J, Grollman AP, Miller JH. 1992b. A repair system for 8-oxo-7, 8-dihydrodeoxyguanine. Biochemistry 31:10964-10968.
36. Mogensen KE, Lewerenz M, Reboul J, Lutfalla G, Uze G. 1999. The type I interferon receptor: structure, function, and evolution of a family business. J Interferon Cytokine Res 19(10): 1069-1098.
37. Murphy KC, Volkert MR. 2012. Structural/functional analysis of the human OXR1 protein: identification of exon 8 as the anti-oxidant encoding function. BMC Mol Biol 13(1):26.
38. Nicol JW, Helt GA, Blanchard SG, Jr., Raja A, Loraine AE. 2009. The Integrated Genome Browser: free software for distribution and exploration of genome-scale datasets. Bioinformatics 25(20):2730-2731.
39. Ottoboni L, Keenan BT, Tamayo P, Kuchroo M, Mesirov JP, Buckle GJ, Khoury SJ, Hafler DA, Weiner HL, De Jager PL. 2012. An RNA profile identifies two subsets of multiple sclerosis patients differing in disease activity. Sci Transl Med 4(153):153ra131.
40. Pal S, Gupta R, Kim H, Wickramasinghe P, Baubet V, Showe LC, Dahmane N, Davuluri RV. 2011. Alternative transcription exceeds alternative splicing in generating the transcriptome diversity of cerebellar development. Genome Res 21(8):1260-1272.
41. Pellegrini S, John J, Shearer M, Kerr IM, Stark GR. 1989. Use of a selectable marker regulated by alpha interferon to obtain mutations in the signaling pathway. Mol Cell Biol 9(11): 4605-4612.
42. Perillo B, Ombra MN, Bertoni A, Cuozzo C, Sacchetti S, Sasso A, Chiariotti L, Malorni A, Abbondanza C, Avvedimento EV. 2008. DNA oxidation as triggered by H3K9me2 de-methylation drives estrogen-induced gene expression. Science 319(5860):202-206.
43. Pestka S, Langer JA, Zoon KC, Samuel CE. 1987. Interferons and their actions. Annu Rev Biochem 56:727-777.
44. Picklo MJ, Olson SJ, Markesbery WR, Montine TJ. 2001. Expression and activities of aldo-keto oxidoreductases in Alzheimer disease. J Neuropathol Exp Neurol 60(7):686-695.
45. Pulit-Penaloza JA, Scherbik SV, Brinton MA. 2012. Activation of Oas1a gene expression by type I IFN requires both STAT1 and STAT2 while only STAT2 is required for Oas1b activation. Virology 425(2):71-81.
46. Rajapakse N, Butterworth M, Kortenkamp A. 2005. Detection of DNA strand breaks and oxidized DNA bases at the single-cell level resulting from exposure to estradiol and hydrox-ylated metabolites. Environ Mol Mutagen 45(4):397-404.
47. Ramsey SA, Knijnenburg TA, Kennedy KA, Zak DE, Gilchrist M, Gold ES, Johnson CD, Lampano AE, Litvak V, Navarro G, Stolyar T, Aderem A, Shmulevich I. 2010. Genome-wide his-tone acetylation data improve prediction of mammalian transcription factor binding sites. Bioinformatics 26(17):2071-2075.
48. Reder AT, Velichko S, Yamaguchi KD, Hamamcioglu K, Ku K, Beekman J, Wagner TC, Perez HD, Salamon H, Croze E. 2008. IFN-beta1b induces transient and variable gene expression in relapsing-remitting multiple sclerosis patients independent of neutralizing antibodies or changes in IFN receptor RNA expression. J Interferon Cytokine Res 28(5):317-331.
49. Rehermann B, Nascimbeni M. 2005. Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol 5(3): 215-229.
50. Rojas-Duran MF, Gilbert WV. 2012. Alternative transcription start site selection leads to large differences in translation activity in yeast. RNA 18(12):2299-2305.
51. Roy D, Cai Q, Felty Q, Narayan S. 2007. Estrogen-induced generation of reactive oxygen and nitrogen species, gene damage, and estrogen-dependent cancers. J Toxicol Environ Health B Crit Rev 10(4):235-257.
52. Russell-Harde D, Knauf M, Croze E. 1995. The use of Zwittergent 3-14 in the purification of recombinant human interferon-beta Ser17 (Betaseron). J Interferon Cytokine Res 15(1):31-37.
53. Shao W, Halachmi S, Brown M. 2002. ERAP140, a conserved tissue-specific nuclear receptor coactivator. Mol Cell Biol 22(10):3358-3372.
54. Stark GR, Darnell JE, Jr. 2012. The JAK-STAT pathway at twenty. Immunity 36(4):503-514.
55. Stark GR, Kerr IM, Williams BR, Silverman RH, Schreiber RD. 1998. How cells respond to interferons. Annu Rev Biochem 67:227-264.
56. Tenoever BR, Ng SL, Chua MA, McWhirter SM, Garcia-Sastre A, Maniatis T. 2007. Multiple functions of the IKK-related kinase IKKepsilon in interferon-mediated antiviral immunity. Science 315(5816):1274-1278.
57. Volkert MR, Wang JY, Elliott NA. 2008. A functional geno-mics approach to identify and characterize oxidation resistance genes. Methods Mol Biol 477:331-342.
58. Waddell SJ, Popper SJ, Rubins KH, Griffiths MJ, Brown PO, Levin M, Relman DA. 2010. Dissecting interferon-induced transcriptional programs in human peripheral blood cells. PLoS One 5(3):e9753.
59. Wagner TC, Velichko S, Chesney SK, Biroc S, Harde D, Vogel D, Croze E. 2004. Interferon receptor expression regulates the antiproliferative effects of interferons on cancer cells and solid tumors. Int J Cancer 111(1):32-42.
60. Wagner TC, Velichko S, Vogel D, Rani MR, Leung S, Ran-sohoff RM, Stark GR, Perez HD, Croze E. 2002. Interferon signaling is dependent on specific tyrosines located within the intracellular domain of IFNAR2c. Expression of IFNAR2c tyrosine mutants in U5A cells. J Biol Chem 277(2):1493-1499.
61. Wang B, Xiong Q, Shi Q, Le X, Abbruzzese JL, Xie K. 2001. Intact nitric oxide synthase II gene is required for interferonbeta-mediated suppression of growth and metastasis of pancreatic adenocarcinoma. Cancer Res 61(1):71-75.
62. Wang JY, Sarker AH, Cooper PK, Volkert MR. 2004. The single-strand DNA binding activity of human PC4 prevents mutagenesis and killing by oxidative DNA damage. Mol Cell Biol 24(13):6084-6093.
63. Watling D, Guschin D, Muller M, Silvennoinen O, Witthuhn BA, Quelle FW, Rogers NC, Schindler C, Stark GR, Ihle JN, et al. 1993. Complementation by the protein tyrosine kinase JAK2 of a mutant cell line defective in the interferon-gamma signal transduction pathway. Nature 366(6451):166-170.
64. Weitzman SA, Gordon LI. 1990. Inflammation and cancer: role of phagocyte-generated oxidants in carcinogenesis. Blood 76(4):655-663.
65. Yamashita R, Sathira NP, Kanai A, Tanimoto K, Arauchi T, Tanaka Y, Hashimoto S, Sugano S, Nakai K, Suzuki Y. 2011. Genome-wide characterization of transcriptional start sites in humans by integrative transcriptome analysis. Genome Res 21(5):775-789.
66. Zhang J, Kramer EG, Mahase S, Dutta DJ, Bonnamain V, Argaw AT, John GR. 2011. Targeting oligodendrocyte protection and remyelination in multiple sclerosis. Mt Sinai J Med 78(2):244-257.